Meet the team

Paul earned his Ph.D. from ETH-Zurich, specializing in Microbiology. His post-doctoral research focused on the modelling of gut microbiota, as well as the characterization of probiotics and prebiotics contributing to projects in Ghana, South Korea, Sweden, and Switzerland, showcasing expertise in biobanking, genetic engineering, and next-generation sequencing. In addition, he is certified by RAPS for Regulatory Affairs. Paul joined Gnubiotics in 2021 as the lead scientist in Microbiology, where he leads the development of microbiome products, next-generation sequencing, biomarker discovery, and innovative advancements in the microbiome field.

Valesca is an immunologist whose PhD in HHU Düsseldorf, centered around cellular immunity followed by a focus on innate immune cell metabolism during her postdoc at the FLI on the isle of Riems. Aiming to drive scientific findings into tangible assets, she focussed on technology transfer. In a TTO, organizations adjoining academia she grew her project and business development skills to guide innovations. Complemented by workexperience in medical affairs at pharmaceutical players Janssen Biotech (a J&J company) and Kyowa Kirin she joined Gnubiotics in 2023 to drive pipeline development.

Yong studied bioactive molecules chemistry in the University of Claude Bernard Lyon 1 in France and has completed his PhD in Macromolecules chemistry in the University of Sciences and Technologies in Lille, France. He has been working on formulation, process development & analytics in Food & Pharma industry since 2015. He joined Gnubiotics in 2018 and he is the process development & analytics manager.
Yong holds a lean six sigma black belt certificate, and he acts as the QC expert in manufacturing.

Valentia is a senior regulatory expert with Intertek. Dr. Valentia Lee-Brotherton has been with Intertek Health Sciences Inc. for over 20 years, working with clients to advance their products in a range of therapeutic areas. As a senior toxicologist, she is involved in the strategic planning, design, and implementation of product development programs for clients, including early-stage IND or CTA investigational products and those nearing registration. As an experienced writer, she is involved in the authorship and review of various types of regulatory documents, including Investigator’s Brochures, INDs, CTAs, and registration dossiers. As a regulatory scientist, she guides them through complex regulatory processes, meetings, and other interactions with health regulators.

Lindsay is an experienced pharmaceutical executive providing consultancy services to the pharmaceutical and biotechnology industries. He is specialized in drug development strategy, toxicology design, regulatory review, and license negotiations. His expertise includes the design of complete drug development strategies for novel therapeutics, providing due diligence on existing drug development packages for companies seek-ing to license compounds from third parties, preclinical representative for companies with the FDA, EMA, and Health Canada, and writing IND/NDA submission documents.

Dolf is an accomplished professional with over two decades of experience in project management, supply chain, and continuous improvement within the life sciences industry, particularly in pharmaceuticals. His expertise encompasses project man-agement, ERP systems implementation, and lean methodologies, along with a deep understanding of cGMP environments. Dolf has demonstrated proficiency in various roles, including business analysis, project leadership, and strategic sourcing, across international settings having worked as Director of Strategic Sourcing at Merck Sharp & Dohme and Head of Procurement at Akzo Nobel – Diosynth. Dolf has a BA in Analytical Chemistry, an Executive MBA and he holds a Lean / 6Sigma Green belt and is certified in production and inventory management.